Cingulate Inc. (CING) NASDAQ
8.69
-0.43(-4.71%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Cingulate Inc.
Address
1901 West 47th Place
Kansas City, KS 66205
United States of America (the)
Phone
913 942 2300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
December 08, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Jennifer L. Callahan | Interim Chief Executive Officer, Senior Vice President, Chief Financial Officer & Secretary | 358,981 | 1971 |
| Shane J. Schaffer | Co-Founder, Chief Executive Officer & Chairman of the Board (Leave of Absence) | 570,781 | 1975 |
| John A. Roberts | Executive Chairman | 52,264 | 1959 |
| Matthew N. Brams | Co-Founder, Executive Vice President & Chief Medical Officer | 244,792 | 1964 |
| Raul R. Silva | Co-Founder, Executive VP & Chief Science Officer | 0 | 1958 |
| Bryan Downey | Chief Commercial Officer | 0 | N/A |
| Nilay Patel | Chief Legal Officer | 0 | N/A |
| Thomas Dalton | Vice President of Investor & Public Relations | 0 | N/A |
Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
